TERCONAZOLE VAGINAL CREAM 0.4%

Manufacturer
Rebel Distributors Corp
Effective date
2010-12-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:10:44

Label at a glance#

ProductTerconazole
Active ingredientTerconazole
Label structure14 sections

Indications and uses

Terconazole Vaginal Cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As Terconazole Vaginal Cream 0.4% is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures.

Dosage and administration

One full applicator (5 g) of Terconazole Vaginal Cream 0.4% (20 mg terconazole) should be administered intravaginally once at bedtime for seven consecutive days. Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect of Terconazole Vaginal Cream 0.4% is not affected by ...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Terconazole Vaginal Cream 0.4% is a white to off-white, water washable cream for intravaginal administration containing 0.4% of the antifungal agent terconazole, cis-1-[p-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-isopropylpiperazine, compounded in a cream base consisting of butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, stearyl alcohol, and purified water.

The structural formula of terconazole is as follows:

Chemical Structure
Chemical Structure

Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two nonhysterectomized subjects with tubal ligations.

Following oral (30 mg) administration of 14C-labelled terconazole, the harmonic half-life of elimination from the blood for the parent terconazole was 6.9 hours (range 4.0-11.3). Terconazole is extensively metabolized; the plasma AUC for terconazole compared to the AUC for total radioactivity was 0.6%. Total radioactivity was eliminated from the blood with a harmonic half-life of 52.2 hours (range 44-60). Excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes.

In vitro, terconazole is highly protein bound (94.9%) and the degree of binding is independent of drug concentration.

Photosensitivity reactions were observed in some normal volunteers following repeated dermal application of terconazole 2.0% and 0.8% creams under conditions of filtered artificial ultraviolet light.

Photosensitivity reactions have not been observed in U.S. and foreign clinical trials in patients who were treated with terconazole vaginal cream 0.4%.

Microbiology

MICROBIOLOGY SECTION

Terconazole exhibits fungicidal activity in vitro against Candida albicans. Antifungal activity has also been demonstrated against other fungi. The MIC values of terconazole against most Lactobacillus spp. typically found in the human vagina were ≥128 mcg/mL, therefore these beneficial bacteria were not affected by drug treatment.

The exact pharmacologic mode of action of terconazole is uncertain; however, it may exert its antifungal activity by the disruption of normal fungal cell membrane permeability. No resistance to terconazole has developed during successive passages of C. albicans.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Terconazole Vaginal Cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As Terconazole Vaginal Cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Patients known to be hypersensitive to terconazole or to any of the components of the cream.

WARNINGS

WARNINGS SECTION

None.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Discontinue use and do not retreat with terconazole if sensitization, irritation, fever, chills or flu-like symptoms are reported during use.

Laboratory Tests

LABORATORY TESTS SECTION

If there is lack of response to terconazole, appropriate microbiologic studies (standard KOH smear and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens.

Drug Interactions

DRUG INTERACTIONS SECTION

The therapeutic effect of Terconazole Vaginal Cream 0.4% is not affected by oral contraceptive usage.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis

SPL UNCLASSIFIED SECTION

Studies to determine the carcinogenic potential of terconazole have not been performed.

Mutagenicity

SPL UNCLASSIFIED SECTION

Terconazole was not mutagenic when tested in vitro for induction of microbial point mutations (Ames test) or for inducing cellular transformation, or in vivo for chromosome breaks (micronucleus test) or dominant lethal mutations in mouse germ cells.

Impairment of Fertility

SPL UNCLASSIFIED SECTION

No impairment of fertility occurred when female rats were administered terconazole orally up to 40 mg/kg/day for a three month period.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C

SPL UNCLASSIFIED SECTION

There was no evidence of teratogenicity when terconazole was administered orally up to 40 mg/kg/day (100 × the recommended intravaginal human dose) in rats, or 20 mg/kg/day in rabbits, or subcutaneously up to 20 mg/kg/day in rats.

Dosages at or below 10 mg/kg/day produced no embryotoxicity; however, there was a delay in fetal ossification at 10 mg/kg/day in rats. There was some evidence of embryotoxicity in rabbits and rats at 20-40 mg/kg. In rats this was reflected as a decrease in litter size and number of viable young and reduced fetal weight. There was also delay in ossification and an increased incidence of skeletal variants.

The no-effect oral dose of 10 mg/kg/day resulted in a mean peak plasma level of terconazole in pregnant rats of 0.176 mcg/mL which exceeds by 44 times the mean peak plasma levels (0.004 mcg/mL) seen in normal subjects after intravaginal administration of terconazole 0.4% vaginal cream. This safety assessment does not account for possible exposure of the fetus through direct transfer of terconazole from the irritated vagina to the fetus by diffusion across amniotic membranes.

Since terconazole is absorbed from the human vagina, it should not be used in the first trimester of pregnancy unless the physician considers it essential to the welfare of the patient.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Animal studies have shown that rat offspring exposed via the milk of treated (40 mg/kg/orally) dams showed decreased survival during the first few post-partum days, but overall pup weight and weight gain were comparable to or greater than controls throughout lactation. Because many drugs are excreted in human milk, and because of the potential for adverse reaction in nursing infants from terconazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and efficacy in children have not been established.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of Terconazole Vaginal Cream 0.4% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

During controlled clinical studies conducted in the United States, 521 patients with vulvovaginal candidiasis were treated with terconazole 0.4% vaginal cream. Based on comparative analyses with placebo, the adverse experiences considered most likely related to terconazole 0.4% vaginal cream were headaches (26% vs. 17% with placebo) and body pain (2.1% vs. 0% with placebo). Vulvovaginal burning (5.2%), itching (2.3%) or irritation (3.1%) occurred less frequently with terconazole 0.4% vaginal cream than with the vehicle placebo. Fever (1.7% vs. 0.5% with placebo) and chills (0.4% vs. 0.0% with placebo) have also been reported. The therapy-related dropout rate was 1.9%. The adverse drug experience on terconazole most frequently causing discontinuation was vulvovaginal itching (0.6%), which was lower than the incidence for placebo (0.9%).

OVERDOSAGE

OVERDOSAGE SECTION

Overdose of terconazole in humans has not been reported to date. In the rat, the oral LD 50 values were found to be 1741 and 849 mg/kg for the male and female, respectively. The oral LD 50 values for the male and female dog were 1280 and ≥ 640 mg/kg, respectively.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

One full applicator (5 g) of Terconazole Vaginal Cream 0.4% (20 mg terconazole) should be administered intravaginally once at bedtime for seven consecutive days.

Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect of Terconazole Vaginal Cream 0.4% is not affected by menstruation.

HOW SUPPLIED

HOW SUPPLIED SECTION

Terconazole Vaginal Cream 0.4% is available in 45 g tubes with a measured-dose applicator. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1
Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532

Repackaged by: Rebel Distributors Corp, Thousand Oaks, CA 91320

SPL PATIENT PACKAGE INSERT SECTION

TERCONAZOLE
VAGINAL CREAM O.4%

PATIENT INSTRUCTIONS

7-DAY THERAPY

Filling the applicator:

1. Remove the cap from the tube. 

Instruction 1Instruction 1
 

 
2. Use the pointed tip on the top of the cap to puncture the seal on the tube. 

Instruction 2Instruction 2
 

 
3. Screw the applicator onto the tube.

Instruction 3Instruction 3

4. Squeeze the tube from the bottom and fill the applicator until the plunger stops.
5. Unscrew the applicator from the tube.

Using the applicator:

  1. Lie on your back with your knees drawn up toward your chest.
  2. Holding the applicator by the barrel, insert the filled applicator into the vagina as far as it will comfortably go.

    Instruction 4Instruction 4

  1. 3.Slowly press the plunger of the applicator to release the cream into the vagina.
  2. 4.Remove the applicator from the vagina.
  3. 5.Apply one applicatorful each night for 7 nights at bedtime, as directed by your doctor.

Cleaning the applicator:

After each use, you should thoroughly clean the applicator by following the procedure below:

1. Pull the plunger out of the barrel.Instruction 5Instruction 5
2. Wash both pieces with lukewarm, soapy water, and dry them thoroughly.
3. Put the applicator back together by gently pushing the plunger into the barrel as far as it will go.

NOTE: Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. See end flap of carton or crimp of tube for lot number and expiration date.

A WORD ABOUT YEAST INFECTIONS

Why do yeast infections occur?

Yeast infections are caused by an organism called Candida (KAN di duh). It may be present in small and harmless amounts in the mouth, digestive tract, and vagina. Sometimes the natural balance of the vagina becomes upset. This may lead to rapid growth of Candida, which results in a yeast infection. Symptoms of a yeast infection include itching, burning, redness, and an abnormal discharge.

Your doctor can make the diagnosis of a yeast infection by evaluating your symptoms and looking at a sample of the discharge under the microscope.

How can I prevent yeast infections?

Certain factors may increase your chance of developing a yeast infection. These factors don't actually cause the problem, but they may create a situation that allows the yeast to grow rapidly.

  • Clothing: Tight jeans, nylon underwear, pantyhose, and wet bathing suits can hold in heat and moisture (two conditions in which yeast organisms thrive). Looser pants or skirts, 100% cotton underwear, and stockings may help avoid this problem.
  • Diet: Cutting down on sweets, milk products, and artificial sweeteners may reduce the risk of yeast infections.
  • Antibiotics: Antibiotics work by eliminating disease-causing organisms. While they are helpful in curing other problems, antibiotics may lead to an overgrowth of Candida in the vagina.
  • Pregnancy: Hormonal changes in the body during pregnancy encourage the growth of yeast. This is a very common time for an infection to occur. Until the baby is born, it may be hard to completely eliminate yeast infections. If you believe you are pregnant, tell your doctor.
  • Menstruation: Sometimes monthly changes in hormone levels may lead to yeast infections.
  • Diabetes: In addition to heat and moisture, yeast thrives on sugar. Because diabetics often have sugar in their urine, their vaginas are rich in this substance. Careful control of diabetes may help prevent yeast infection.

Controlling these factors can help eliminate yeast infections and may prevent them from coming back.

Some other helpful tips:

  1. For best results, be sure to use the medication as prescribed by your doctor, even if you feel better very quickly.
  2. Avoid sexual intercourse, if your doctor advises you to do so.
  3. If your partner has any penile itching, redness, or discomfort, he should consult his physician and mention that you are being treated for a yeast infection.
  4. You can use the medication even if you are having your menstrual period. However, you should not use tampons because they may absorb the medication. Instead, use external pads or napkins until you have finished your medication. You may also wish to wear a sanitary napkin if the vaginal medication leaks.
  5. Dry the genital area thoroughly after showering, bathing, or swimming. Change out of a wet bathing suit or damp exercise clothes as soon as possible. A dry environment is less likely to encourage the growth of yeast.
  6. Wipe from front to rear (away from the vagina) after a bowel movement.
  7. Don't douche unless your doctor specifically tells you to do so. Douching may disturb the vaginal balance.
  8. Don't scratch if you can help it. Scratching can cause more irritation and spread the infection.
  9. Discuss with your physician any medication you are already taking. Certain types of medication can make your vagina more susceptible to infection.
  10. Eat nutritious meals to promote your general health.

Mfd. by:
Taro Pharmaceuticals Inc.
Brampton, Ontario, Canada L6T 1C1

Dist. by:
Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, NY 10532

Repackaged by:

Rebel Distributors Corp

Thousand Oaks, CA 91320

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Terconazole Vaginal 0.4%Terconazole Vaginal 0.4%

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
313226terconazole 0.4 % Vaginal CreamPSN1
313226terconazole 4 MG/ML Vaginal CreamSCD1
313226terconazole 0.4 % Vaginal CreamSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TERCONAZOLE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a1f2acc3-46a1-8c88-4468-5826c2e9fea6Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
21695-844-452019-09-24C16284748780-1934fe258-4a40-48b1-e053-8cdaa90a720aTERCONAZOLE VAGINAL CREAM 0.4%

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
21695-844-45Terconazole45 g in 1 TUBECREAM451
21695-844-45Terconazole1 in 1 CARTONCREAM11

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
21695-844TERCONAZOLE CREAM [REBEL DISTRIBUTORS CORP]1Legacy NDC, 2 package rows20101210_5527cd23-567b-4019-8e5c-f71ee7ed2689.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
21695-844-45GM - Gram21695-844286ccb1d-7e95-4e44-96d5-59fd3a97905d12012-07-24
51672-1304-6GM - Gram51672-13043068858f-1322-4c18-8d7f-df11120718b112012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
TerconazoleACTIVE INGREDIENT0KJ2VE664U1
TerconazoleACTIVE MOIETY0KJ2VE664U1
butylated hydroxyanisoleINACTIVE INGREDIENTREK4960K2U1
cetyl alcoholINACTIVE INGREDIENT936JST6JCN1
isopropyl myristateINACTIVE INGREDIENT0RE8K4LNJS1
POLYSORBATE 60INACTIVE INGREDIENTCAL22UVI4M1
POLYSORBATE 80INACTIVE INGREDIENT6OZP39ZG8H1
propylene glycolINACTIVE INGREDIENT6DC9Q167V31
stearyl alcoholINACTIVE INGREDIENT2KR89I4H1Y1
waterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
21695-84421695-844-45
51672-1304

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 7 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
cetyl alcoholCETYL ALCOHOL936JST6JCNCREAM / VAGINAL200 mgExact identifier — unii+route+dosage form
POLYSORBATE 60POLYSORBATE 60CAL22UVI4MCREAM / VAGINAL200 mgExact identifier — unii+route+dosage form
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HCREAM / VAGINAL0.4 %w/wExact identifier — unii+route+dosage form
isopropyl myristateISOPROPYL MYRISTATE0RE8K4LNJSCREAM / VAGINAL50 mgExact identifier — unii+route+dosage form
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CREAM / VAGINAL1225 mgExact identifier — unii+route+dosage form
stearyl alcoholSTEARYL ALCOHOL2KR89I4H1YCREAM / VAGINAL425 mgExact identifier — unii+route+dosage form
butylated hydroxyanisoleBUTYLATED HYDROXYANISOLEREK4960K2UCREAM / VAGINAL0.03 %w/wExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A076043-001TERCONAZOLETERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A076043-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-1984e616aacf4f…
2026-08-18 06:07:402026-07A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-1931067a03dcf5…
2025-08-23 18:47 UTC2025-08A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-196a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-1903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-192680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-195bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-1979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-191e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-198072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-195c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-195d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-194b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-1974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-1987673890dc5c…
2021-03-12 10:30 UTC2021-03A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-195aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-198869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-193f01610625f2…
2019-09-15 20:21 UTC2019-09A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19b00525d2431f…
2019-07-19 19:46 UTC2019-07A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-196a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-191c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-199b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-193f0d92c62455…
2023-05-13 08:27 UTC2023-05A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19053a50430f4f…
2023-01-26 05:58 UTC2023-01A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-193bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-193a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A076043-001TERCONAZOLE0.4%CREAM / VAGINALABRS2005-01-19f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A076043-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A076043-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076043-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076043-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A076043-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076043-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076043-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076043-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076043-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076043-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076043-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076043-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076043-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076043-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076043-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076043-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076043-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076043-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076043-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076043-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076043-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076043-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076043-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A076043-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076043-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076043-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076043-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A076043-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A076043-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076043-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076043-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076043-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076043-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A076043-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A076043-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A076043-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A076043-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A076043-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A076043-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A076043-001AB1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TerconazoleTERCONAZOLESun Pharmaceutical Industries, Inc.2b3923b5-0a97-428c-b8d2-4a3ceb3447a12025-05-27Warnings, Adverse reactionsExact identifier
ndc (product): 51672-1304
5527cd23-567b-4019-8e5c-f71ee7ed26895527cd23-567b-4019-8e5c-f71ee7ed26892010-12-01Warnings, Adverse reactionsExact identifier
spl id: 5527cd23-567b-4019-8e5c-f71ee7ed2689
spl set id: 5527cd23-567b-4019-8e5c-f71ee7ed2689

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.